Prostate Cancer Vaccine May Get FDA Approval
January 5, 2012 -- With efforts from the Prostate Cancer Foundation and the U.S. prostate cancer advocacy community, led by the Prostate Cancer Roundtable, the 2012 budget for Congressionally Directed Medical Research Programs was preserved. For the more than 2 million American men and their families facing prostate cancer and the over 242,000 who will be diagnosed in 2012, the budget allocation means that $80 million will remain directed toward prostate cancer research.
On December 15, 2011, the House released an Omnibus appropriations bill (H.R. 2055) and statement of managers, which included Labor, Health and Human Services, Education and Related Agencies (L-HHS). Passed by the House on December 16, 2011 and by the Senate on December 17, 2011, President Barack Obama signed the bill into law on December 23, 2011.
We should all be relieved to see the preservation of this important research budget for one more year. But there’s more work ahead.
While policymakers are seeking ways to reduce costs, our shared vision to cure more and overtreat less is even more urgent. These two goals are not in opposition. Cancer research and prevention is an investment, not an expense that can save millions of lives and trillions of dollars. The National Cancer Institute estimates that a 20-percent reduction in cancer mortality would be worth $20 trillion to the U.S. economy—far more than the federal debt.
A special thank you to all organizations involved in the Prostate Cancer Roundtable who have worked tirelessly to secure this funding:
- Ed Randall's Fans for a Cure
- Malecare Men's Health Network
- National Alliance of State Prostate Cancer Coalitions
- Prostate Cancer Foundation
- Prostate Cancer International
- Prostate Conditions Education Council
- Prostate Health Education Network
- The Prostate Net
- Us TOO International
- Women Against Prostate Cancer ZERO-The Project to End Prostate Cancer